Skip to main content Skip to main navigation menu Skip to site footer

The role of tumor necrosis factor-alpha (TNF-α) inhibitor in steven johnson syndrome/toxic epidermal necrolysis (SJS/TEN) management: a systematic review


Background. Steven Johnson Syndrome and Toxic Epidermal Necrolysis are dermatologic emergencies with high mortality rates characterized by extensive skin involvement. TNF-α has a role in inducing the production of granulysin that enhances keratinocyte cell death. Thus, the use of TNF-α inhibitors such as etanercept and infliximab is promising to halt the disease progression. This systematic review aims to evaluate the efficacy of TNF-α inhibitor in SJS/TEN management.

Method. A systematic review using an online database was conducted based on PRISMA guidelines. Inclusion criteria were studied about the role of TNF-α inhibitor in SJS/TEN management. The exclusion criteria were a letter to the editor, commentary report, review, meta-analysis, study not used humans as a study subject, not available in full text and not in English or Bahasa Indonesia.

Result. Fourteen studies are included in this systematic review consisting of ten case reports, three cohort retrospective studies, and one randomized controlled trial. TNF-α inhibitors such as etanercept and infliximab are beneficial for SJS/TEN management because they accelerate skin healing time and re-epithelization, reduce in-hospital duration and mortality rate, and minimal complications and side effects. TNF-α inhibitors should be given quickly after the disease onset, and combination with other immunosuppressive agents should be avoided to prevent the excessive immunosuppressive effect.

Conclusion. TNF-α inhibitors such as etanercept and infliximab promise therapy to halt SJS/TEN progression.  


  1. Oshikoya KA, Ogunyinka IA, Ogar CK, Abiola A, Ibrahim A, Oreagba IA. Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis were reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017. Therapeutic Advances in Drug Safety. 2020; 11: 2042098620905998.
  2. Pearson DR, Margolis DJ. Chapter 44: Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). Fitzpatrick’s Dermatology in General Medicine. 9th ed. United States of America: McGraw-Hill. 2019; 9(I): p.767-79
  3. Lin CC, Chen CB, Wang CW, Hung SI, Chung WH. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Review of Clinical Immunology. 2020; 16(4):373-387.
  4. Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis. 2018; 101(1): E15-E21.
  5. Bakir M, Almeshal H, Alturki R, Obaid S, Almazroo A.Toxic Epidermal Necrolysis Post COVID-19 Vaccination-First Reported Case. Cureus. 2021;13(8). DOI: 10.7759/cureus.17215
  6. Chafranska L, Saunte DM, Behrendt N, Nygaard U, Christensen RJ, Sand C, Jemec GB. Pediatric toxic epidermal necrolysis treated successfully with infliximab. Pediatric Dermatology. 2019; 36(3): 342-345. DOI: 10.1111/pde.13778
  7. Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatology online journal. 2018; 24(1). DOI: 10.5070/D3241037941
  8. Coulombe J, Belzile E, Duhamel A, Rault P, Buteau C, DeBruycker JJ, Bussières JF. Pediatric SJS/TEN is subdued by a combination of dexamethasone, cyclosporine, and etanercept. Journal of cutaneous medicine and surgery. 2019; 23(5): 547-550. DOI: 10.1177/1203475419861078
  9. Dreyer SD, Torres J, Stoddard M, Leavitt E, Sutton A, Aleshin M, Worswick S. Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cutis. 2021;107(6): E22-E28. DOI:10.12788/cutis.0288
  10. Faris J, Wilson J, Dolman HS, Isaacson A, Baylor AE, Tyburski JG, White MT. A cautionary tale of etanercept use in patients with toxic epidermal necrolysis. Journal of Burn Care & Research. 2021; 42(3): 586-589. DOI:
  11. Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. Journal of Cutaneous Medicine and Surgery. 2018; 22(5): 514-515.
  12. Pham CH, Gillenwater TJ, Nagengast E, McCullough MC, Peng DH, Garner WL. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Burns. 2019; 45(7):1634-1638.
  13. Shen MH, Liu MT, Chung WH, Lu CW. Toxic epidermal necrolysis induced by human herpesvirus 7 treated with a tumor necrosis factor‐α inhibitor. The Journal of Dermatology. 2020; 47(10): 1179-1181. doi: 10.1111/1346-8138.15493
  14. So N, Leavitt E, Aleshin M, Worswick S. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential. Dermatologic Therapy. 2018; 31(5): e12684. DOI: 10.1111/dth.12684
  15. Torres‐Navarro I, Briz‐Redón Á, Botella‐Casas G, Sahuquillo‐Torralba A, Calle‐Andrino A, de Unamuno‐Bustos B, et al. Accuracy of SCORTEN and ABCD‐10 to predict mortality and the influence of renal function in Stevens–Johnson syndrome/toxic epidermal necrolysis. The Journal of Dermatology. 2020; 47(10): 1182-1186. doi: 10.1111/1346-8138.15490
  16. Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chung WH. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. The Journal of clinical investigation. 2018; 128(3): 985-996. DOI:
  17. Wang F, Gao X, Chen X, Tang X, Chen H, Han J. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. The Journal of Dermatology. 2019; 46(11): 1035-1038. doi: 10.1111/1346-8138.15058
  18. Zander E, Hintze TD, Sallee B, Allen P, Miller JL, Sagdeo M. Treatment of Toxic Epidermal Necrolysis with Etanercept in a Pediatric Patient. The Journal of Pediatric Pharmacology and Therapeutics: JPPT. 2021; 26(7): 758. DOI: 10.5863/1551-6776-26.7.758
  19. Goffe B, Cather JC. Etanercept: an overview. Journal of the American Academy of Dermatology. 2003; 49(2): 105-111.
  20. Kirman I, Whelan RL, Nielsen OH. Infliximab: mechanism of action beyond TNF-α neutralization in inflammatory bowel disease. European journal of gastroenterology & hepatology. 2004; 16(7): 639-641. doi: 10.1097/01.meg.0000108345.41221.c2
  21. Sachdeva M, Maliyar K, Ponzo MG. A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Journal of Cutaneous Medicine and Surgery. 2021; 25(6): 598-615. DOI: 10.1177/1203475421993779
  22. Zhang S, Tang S, Li S, Pan Y, Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. Journal of Dermatological Treatment. 2020; 31(1): 66-73.

How to Cite

Kurnia, I. Y. (2022). The role of tumor necrosis factor-alpha (TNF-α) inhibitor in steven johnson syndrome/toxic epidermal necrolysis (SJS/TEN) management: a systematic review. Intisari Sains Medis, 13(2), 436–422.




Search Panel

Icasia Yuseli Kurnia
Google Scholar
ISM Journal